Choose the correct answer. In an in vivo phenotypic assay:

Question

BlackTom AI · Accepted Answer

Phenotypic in vivo assays require an animal model that reproduces the relevant disease phenotype seen in humans so that compound effects on whole‑organism outcomes can be meaningfully interpreted. Key knowledge points: definition of phenotypic screening, difference between in vivo and target‑based assays, the role of model validation, and what constitutes a “hit” in phenotypic studies.

1) Relevant concepts:
- Phenotypic assay: measures a biological outcome or disease trait (behavior, pathology, survival, biomarker change) without prespecifying a molecular target.
- In vivo: performed in living animals; model validity (face, construct, and predictive validity) ensures that results translate toward human disease.
- Target knowledge and arbitrary correction factors are not inherent requirements of phenotypic in vivo assays.

2) Step‑by‑step reasoning:
- Because phenotypic assays judge compounds by their effect on an organismal phenotype, the animal model must faithfully reproduce the disease trait(s) you intend to modify; otherwise any observed effect cannot be related to the human condition.
- Knowing the molecular target beforehand is characteristic of target‑based screens; it does not increase the number of hits in an unbiased phenotypic in vivo screen.
- There is no standard rule that IC50 values from in vivo phenotypic screens require multiplication by a 2.5 correction factor—such a statement is arbitrary and incorrect.
- If the animal model does not exhibit the disease trait at baseline, you cannot measure therapeutic benefit; the model must show the trait being targeted so treatment effects are detectable.

3) Calculations: none required.

4) Why the correct answer is correct:
- Option (a) states the necessity of prior validation of the animal model to correlate with the human disease — this is essential to interpret phenotypic in vivo results and to have predictive value for human therapeutics.

5) Why other options are incorrect:
- (b) Incorrect: prior knowledge of a target is irrelevant to the principle of phenotypic screening and does not automatically increase hit rate.
- (c) Incorrect: no universal correction factor for IC50 exists; IC50 interpretation depends on assay specifics and pharmacokinetics.
- (d) Incorrect: the model must display the disease trait so improvement or modulation can be measured.

Conclusion: The correct choice is (a). This matches the provided answer.

Choose the correct answer. In an in vivo phenotypic assay:单项选择题

类似问题

Is the following statement true or false? In the products of methylation-hydrolysis, every -OH group corresponds to the position of a glycosidic bond in the starting polysaccharide.

Which of the follwoing structures represents amylopectin?

Which of the following is true about an aldopentose?I. It is a monosaccharide.II. It contains a CHO groupIII. It is a disaccharide.IV. It is an oligosaccharide.

For stock A, we have 𝛽 𝑖 = 0.70. Suppose the expected market risk premium next year is 9% and the risk-free rate is 3%. What is the expected return of this stock based on the CAPM? (Please answer in % and round to 2 decimal places. If the answer is 8.057%, then in the box, write 8.06)

The following graph shows the Security Market Line in the current economy. If a stock has a β of 1.2, what is the expected return of this stock based on the CAPM? (Please answer in % and round to 2 decimal places. If the answer is 8.057%, then in the box, write 8.06)

更多留学生实用工具

智能学习助手

风格化写作助手

论文查重助手

文献引用助手

课堂转译助手

课堂笔记助手

Quiz搜索助手

学校历年真题

智能刷题助手

智能匹配练习

希望你的学习变得更简单